Monoamine Oxidase, Monoamine-Oxidase-Inhibiting Drugs, and Human Behavior

  • Dennis L. Murphy

Abstract

Monoamine-oxidase- (MAO)-inhibiting drugs, which reduce the oxidative deamination of the brain biogenic amine neurotransmitters, were the first effective antidepressant agents used in medicine. Although there have been many studies of the clinical efficacy of these agents, there have been only a handful of reports examining their other effects on human behavior and psychological function. There are also only a small number of studies of the effects of in vivo treatment with MAO-inhibiting drugs on human monoamine oxidase activity.

Keywords

Dopamine Testosterone Catecholamine Lamine Monoamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akindele, M. O., Evans, J. I., and Oswald, I., 1970, Mono-amine oxidase inhibitors, sleep and mood, Electroenceph. Clin. Neurophysiol. 29:447–456.CrossRefGoogle Scholar
  2. Anthony, M., and Lance, J. W., 1969, Monoamine oxidase inhibition in the treatment of migraine, Arch. Neurol. 21:263–268.PubMedGoogle Scholar
  3. Benson, P. F., and Southgate, J., 1971, Diminished activity of platelet monoamine oxidase in Down’s syndrome, Am. J. Hum. Genet. 23:211–214.PubMedGoogle Scholar
  4. Belmaker, R. H., Murphy, D. L., Wyatt, R. J., and Loriaux, D. L., 1974, Human platelet monoamine oxidase changes during the menstrual cycle, Arch. Gen. Psychiatry 31:553–556.PubMedGoogle Scholar
  5. Birkhauser, V. H., 1941, Cholinesterase and mono-aminoxydase in zetralen nervensystem, Schweiz. Med. Wochenschr. 22:750–752.Google Scholar
  6. Blaschko, H., 1974, The natural history of amine oxidases, Rev. Physiol. Biochem. Pharmacol. 70:83–148.PubMedCrossRefGoogle Scholar
  7. Bockar, J., Roth, R., and Heninger, G., 1974, Increased human platelet monoamine oxidase during lithium carbonate therapy, Life Sci. 15:2109–2118.CrossRefGoogle Scholar
  8. Buchsbaum, M., Coursey, R. D., and Murphy, D. L., 1976, The biochemical high risk paradigm: Behavioral and familial correlates of low platelet monoamine oxidase activity, Science 194:339–341.PubMedCrossRefGoogle Scholar
  9. Carpenter, W. T., Murphy, D. L., and Wyatt, R. J., 1975, Platelet monoamine oxidase activity in acute schizophrenia, Am. J. Psychiatry 132:438–441.PubMedGoogle Scholar
  10. Cole, J. O., 1964, Therapeutic efficacy of antidepressant drugs, J. Am. Med. Assoc. 190:448–455.Google Scholar
  11. Collins, G. G. S., and Sandler, M., 1971, Human blood platelet monoamine oxidase, Biochem. Pharmacol. 20:289–296.PubMedCrossRefGoogle Scholar
  12. Collins, G. G. S., Sandler, M., Williams, E. D., and Youdim, M. B. H., 1970, Multiple forms of human brain mitochondrial monoamine oxidase, Nature 225:817–819.PubMedCrossRefGoogle Scholar
  13. Domino, E. F., and Khanna, S. S., 1976, Decreased blood platelet MAO activity in unmedicated chronic schizophrenic patients, Am. J. Psychiatry 133:323–326.PubMedGoogle Scholar
  14. Domino, E. F., Krause, R. R., and Bowers, J., 1973, Various enzymes involved with putative transmitters, Arch. Gen. Psychiatry 29:195–201.PubMedGoogle Scholar
  15. Donnelly, C. H., and Murphy, D. L., 1977, Substrate-and inhibitor-related characteristics of human platelet monoamine oxidase, Biochem. Pharmacol. 26:853–858.PubMedCrossRefGoogle Scholar
  16. Dunleavy, D. L. F., and Oswald, I., 1973, Phenelzine, mood response, and sleep, Arch. Gen. Psychiatry 28:353–396.PubMedGoogle Scholar
  17. Edwards, D. J., and Burns, M. O., 1974, Effects of tricyclic antidepressants upon platelet monoamine oxidase, Life Sci. 15:2045–2058.CrossRefGoogle Scholar
  18. Edwards, D. J., and Chang, S-S., 1975, Evidence for interacting catalytic sites of human platelet monoamine oxidase, Biochem. Biophys. Res. Commun. 65:1018–1025.PubMedCrossRefGoogle Scholar
  19. Epps, H. M. R., 1945, The development of amine oxidase activity by human tissues after birth, Biochem. J. 39:37–42.PubMedGoogle Scholar
  20. Feldstein, A., Hoagland, H., Wong, K. K., Oktem, M. R., and Freeman, H., 1964, MAO activity in relation to depression, Am. J. Psychiatry 131:1392–1394.Google Scholar
  21. Friedman, E., Shopsin, B., Sathananthan, G., and Gershon, S., 1974, Blood platelet MAO activity in psychiatric patients, Am. J. Psychiatry 131:1392–1394.PubMedGoogle Scholar
  22. Ganrot, P. O., Rosengren, E., and Gottfries, C. G., 1962, Conversion of β-mercaptopyruvate to 2-mercaptoethanol by yeast enzymes, Experientia 18:260–261.PubMedCrossRefGoogle Scholar
  23. Gennser, G., and Studnitz, W. V., 1969, Monoamine oxidase, catechol-O-methyltransferase and phenylethanolamine-N-methyltransferase activity in para-aortic tissue of the human fetus, Scand. J. Clin. Lab. Invest. 24:169–171.PubMedCrossRefGoogle Scholar
  24. Gentil, V., Greenwood, M. H., and Lader, M. H., 1975, The effect of adrenaline on human platelet MAO, Psychopharmacologia 44:187–194.PubMedCrossRefGoogle Scholar
  25. Gjessing, L. R., 1964, Studies of periodic catatonia-II The urinary excretion of phenolic amines and acids with and without loads of different drugs, J. Psychiatr. Res. 2:149–162.CrossRefGoogle Scholar
  26. Goridis, C., and Neff, N. H., 1972, Evidence for specific monoamine oxidases in human sympathetic nerve and pineal gland, Proc. Soc. Exp. Biol. Med. 140:573–574.PubMedGoogle Scholar
  27. Gottfries, C.-G., Oreland, L., Wiberg, A., and Winblad, B., 1974, Brain levels of monoamine oxidase in depression, Lancet 2:360–361.PubMedCrossRefGoogle Scholar
  28. Grant, E. C. G., and Pryse-Davies, J., 1968, Effect of oral contraceptives on depressive mood changes and on endometrial monoamine oxidase and phosphatases, Br. Med. J. 3:777–780.PubMedCrossRefGoogle Scholar
  29. Grote, S. S., Moses, S. G., Robins, E., Hudgens, R. W., and Croninger, A. B., 1974, A study of selected catecholamine metabolizing enzymes: A comparison of depressive suicides and alcoholic suicides with controls, J. Neurochem. 23:791–802.PubMedCrossRefGoogle Scholar
  30. Hall, D. W. R., Logan, B. W., and Parsons, G. H., 1969, Further studies on the inhibition of monoamine oxidase by M & B 9302 (clorgyline)-I. Substrate specificity in various mammalian species, Biochem. Pharmacol. 18:1447–1454.PubMedCrossRefGoogle Scholar
  31. Harkonen, M., and Penttila, A., 1971, Catecholamines, monoamine oxidase and cholines-terase activity in the human sympathetic ganglion, Acta Physiol. Scand. 82:310–321.PubMedCrossRefGoogle Scholar
  32. Harris, H., 1971, The Principles of Human Biochemical Genetics, p. 140, American Elsevier, New York.Google Scholar
  33. Hendley, E. D., and Snyder, S. H., 1968, Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy, Nature 220:1330–1331.PubMedCrossRefGoogle Scholar
  34. Herkert, E. E., and Keup, W., 1969, Excretion patterns of tryptamine, indole-acetic acid, and their correlation with mental changes in schizophrenia patients under medication with alpha-methyldopa, Psychopharmacologia 15:48–59.PubMedCrossRefGoogle Scholar
  35. Himwich, H. E., 1970, Indoleamines and the schizophrenias, in: Biochemistry Schizophrenias, and Affective Illnesses (H. E. Himwich, ed.), pp. 79–122, Williams and Wilkins, Baltimore.Google Scholar
  36. Houslay, M. D., and Tipton, K. F., 1973, The nature of the electrophoretically separable multiple forms of rat liver monoamine oxidase, Biochem. J. 135:173–186.PubMedGoogle Scholar
  37. Houslay, M. D., Garrett, N. J., and Tipton, K. F., 1974, Mixed substrate experiments with human brain monoamine oxidase, Biochem. Pharmacol. 23:1937–1944.PubMedCrossRefGoogle Scholar
  38. Huszti, Z., 1972, Kinetic studies on rat brain monoamine oxidase, Mol. Pharmacol. 8:385–397.PubMedGoogle Scholar
  39. Jain, M. L., and Sands, F. L., 1974, Electrophoretic homogeneity of solubilized human brain monoamine oxidase, J. Neurochem. 23:1291–1293.PubMedCrossRefGoogle Scholar
  40. Jain, M., Bakutis, E., Gayle, T., and Lansky, P., 1974, Some kinetic and inhibition properties of human brain mitochondrial monoamine oxidase (EC 1.4.3.4), Neurobiology 4:180–190.PubMedGoogle Scholar
  41. Johnston, J. P., 1968, Some observations upon a new inhibitor of monoamine oxidase in brain tissue, Biochem. Pharmacol. 17:1285–1297.PubMedCrossRefGoogle Scholar
  42. Klein, D. F., and Davis, J. M., 1969, Diagnosis and Drug Treatment of Psychiatric Disorders, pp. 205–211, Williams and Wilkins, Baltimore.Google Scholar
  43. Kojima, K., Iida, M., Majima, Y., and Okada, S., 1961, Histochemical studies on monoamine oxidase (MAO) of the human retina, Jpn. J. Opthalmol. 5:205–210.Google Scholar
  44. Kupfer, D., and Bowers, M. B., 1973, REM sleep and central monoamine oxidase inhibition, Psychopharmacologia 27:183–190.CrossRefGoogle Scholar
  45. Levine, R. J., and Sjoerdsma, A., 1963, Estimation of monoamine oxidase activity in man: Techniques and applications, Ann. N.Y. Acad. Sci. 107:966–974.PubMedCrossRefGoogle Scholar
  46. Lott, I. T., Chase, T. H., and Murphy, D. L., 1972, Down’s syndrome: Transport, storage and metabolism of serotonin in blood platelets, Pediatr. Res. 6:730–735.PubMedCrossRefGoogle Scholar
  47. Lovenberg, W., Dixon, E., Keiser, H. R., and Sjoerdsma, A., 1968, A comparison of amine oxidase activity in human skin, rat skin and rat liver: Relevance to collagen cross-linking, Biochem. Pharmacol. 17:1117–1120.PubMedCrossRefGoogle Scholar
  48. MacLean, R., Nicholson, W. J., Pare, C. M., and Stacey, R. S., 1965, Effect of monoamine-oxidase inhibitors on the concentrations of 5-hydroxytryptamine in the human brain, Lancet 2:205–208.CrossRefGoogle Scholar
  49. Marjerrison, G., 1966, The effects of pheniprazine on visual imagery in perceptual deprivation, J. Nero. Ment. Dis. 142:254–264.CrossRefGoogle Scholar
  50. McEwen, C. M., Jr., Sasaki, G., and Lenz, W. R., 1968, Human liver mitochondrial monoamine oxidase. I. Kinetic studies of model interactions, J. Biol. Chem. 243:5217–5225.PubMedGoogle Scholar
  51. McEwen, C. M., Jr., Sasaki, G., and Jones, D. C., 1969a, Human liver mitochondrial monoamine oxidase. II. Determinants of substrate and inhibitor specificities, Biochemistry 8:3952–3962.PubMedCrossRefGoogle Scholar
  52. McEwen, C. M., Jr., Sasaki, G., and Jones, D. C., 1969b, Human liver mitochondrial monoamine oxidase. III. Kinetic studies concerning time-dependent inhibitions, Bio-chemistry 8:3963–3972.Google Scholar
  53. Meltzer, H. Y., and Stahl, S. M., 1974, Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients, Res. Commun. Chem. Pathol. Pharmacol. 7:419–431.PubMedGoogle Scholar
  54. Miura, Y., Mendez, R., and Dequattro, V., 1973, Norepinephrine (NE) content and activities of enzymes regulating NE biosynthesis and metabolism in human vas deferens, Fed. Proc. 32:770.Google Scholar
  55. Murphy, D. L., 1972a, Amine precursors, amines and false neurotransmitters in depressed patients, Am. J. Psychiatry 129:141–148.PubMedGoogle Scholar
  56. Murphy, D. L., 1972b, L-Dopa, behavioral activation and psychopathology, in: Neurotransmitters (I. J. Kopin, ed.), Res. Publ. Assoc. Res. Nero. Ment. Dis. 50:472–493.Google Scholar
  57. Murphy, D. L., 1973, Technical strategies for the study of catecholamines in man, in: Frontiers in Catecholamine Research (F. Usdin and S. Snyder, eds.), pp. 1077–1082, Pergamon Press, Oxford.Google Scholar
  58. Murphy, D. L., 1977, The behavioral toxicity of monoamine oxidase-inhibiting antidepressants, Adv. Pharmacol. Chemother. 14:72–105.Google Scholar
  59. Murphy, D. L., and Costa, J. L., 1975, Utilization of cellular studies of neurotransmitter-related enzymes and transport processes in man for the investigation of biological factors in behavioral disorders, in: Recent Biological Studies of Depressive Illness (U. Mendels, ed.), pp. 223–236, Spectrum Publications, New York.Google Scholar
  60. Murphy, D. L., and Donnelly, C. H., 1974, Monoamine oxidase in man: Enzyme characteristics in platelets, plasma and other human tissues, in: Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes (E. Usdin, ed.), pp. 71–85, Raven Press, New York.Google Scholar
  61. Murphy, D. L., and Weiss, R., 1972, Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients, Am. J. Psychiatry 128:1351–1357.PubMedGoogle Scholar
  62. Murphy, D. L., and Wyatt, R. J., 1972, Reduced monoamine oxidase activity in blood platelets from schizophrenic patients, Nature 238:225–226.PubMedCrossRefGoogle Scholar
  63. Murphy, D. L., and Wyatt, R. J., 1975, Enzyme studies in the major psychiatric disorders: 1. Catechol-0-methyl-transferase, monoamine oxidase in the affective disorders, and factors affecting some behavior-related enzyme activities, in: The Biology of the Major Psychoses: A Comparative Analysis (D. X. Freedman, ed.), pp. 289–296, Raven Press, New York.Google Scholar
  64. Murphy, D. L., Belmaker, R., and Wyatt, R. J., 1974, Monoamine oxidase in schizophrenia and other behavioral disorders, J. Psychiatr. Res. 11:221–247.PubMedCrossRefGoogle Scholar
  65. Murphy, D. L., Cahan, D. H., and Molinoef, P. B., 1975, Occurrence, transport and storage of octopamine in human blood platelets. Clin. Pharmacol. Ther. 18:587–593.PubMedGoogle Scholar
  66. Murphy, D. L., Wright, C., Buchsbaum, M., Costa, J., Nichols, A., and Wyatt, R. J., 1976a, Platelet and plasma amine oxidase activity in 680 normals: Sex and age differences and stability over time Biochem. Med. 16:254–265.CrossRefGoogle Scholar
  67. Murphy, D. L., Donnelly, C. H., Miller, L., and Wyatt, R. J., 1976b, Platelet monoamine oxidase in chronic schizophrenia: Some enzyme characteristics relevant to reduced activity Arch. Gen. Psychiat. 33:1377–1381.PubMedGoogle Scholar
  68. Murphy, D. L., Belmaker, R. H., Buchsbaum, M., Wyatt, R. J., Martin, N. F., and Ciaranello, R., 1977a, Biogenic amine-related enzymes and personality variations in normals, Psychol. Med. 7:149–157.PubMedCrossRefGoogle Scholar
  69. Murphy, D. L., Brand, E., Goldman, T., Baker, M., Wright, C., van Kammen, D., and Gordon, E., 1977b, Platelet and plasma amine oxidase inhibition and urinary, amine excretion changes during phenelzine treatment, J. Nerv. Ment. Dis. 164:129–134.PubMedCrossRefGoogle Scholar
  70. Murphy, D. L., Belmaker, R., Carpenter, W. T., and Wyatt, R. J., 1977c, Monoamine oxidase in chronic schizophrenia: Studies of hormonal and other factors affecting enzyme activity. Brit. J. Psychiat. 130:151–158.PubMedCrossRefGoogle Scholar
  71. Nagatsu, T., Yamamoto, T., and Harada, M., 1970, Purification and properties of human brain mitochondrial monoamine oxidase, Enzymologia 39:15–25.PubMedGoogle Scholar
  72. Nies, A., Robinson, D. S., Lamborn, K. R., and Lambert, R. P., 1973, Genetic control of platelet and plasma monoamine oxidase activity, Arch. Gen. Psychiatry 28:834–838.PubMedGoogle Scholar
  73. Nies, A., Robinson, D. S., Harris, L. S., and Lamborn, K. R., 1974, Comparison of monoamine oxidase substrate activities in twins, schizophrenics, depressives, and controls, in: Ncuropsychopharmacology of Monoamines and Their Regulatory Enzymes (E. Usdin, ed.), pp. 59–70, Raven Press, New York.Google Scholar
  74. Oreland, L., 1971, Purification and properties of pig liver mitochondrial monoamine oxidase, Arch. Biochem. Biophys. 146:410–421.PubMedCrossRefGoogle Scholar
  75. Paasonen, M. K., and Solatunturi, E., 1965, Monoamine oxidase in mammalian blood platelets. Ann. Med. Exp. Biol. Fenn. 43:98–100.PubMedGoogle Scholar
  76. Paasonen, M. K., Solatunturi, E., and Kiyalo, E., 1964, Monoamine oxidase activity of blood platelets and their ability to store 5-hydroxytryptamine in some mental deficiencies, Psychopharmacologia 6:120–124.PubMedCrossRefGoogle Scholar
  77. Pandey, G. N., Dorus, E. B., Dekirmenjian, H., and Davis, J. M., 1975, Effect of lithium treatment on blood COMT and platelet MAO in normal human subjects, Fed. Proc. 34:778.Google Scholar
  78. Pletcher, A., Gey, F. K., and Burkand, W. P., 1966, Inhibitors of monoamine oxidase and decarboxylase of aromatic amine acids, Handb. Exp. Pharmacol. 19:953–1047.Google Scholar
  79. Redmond, D. E., Jr., and Murphy, D. L., 1975, Behavioral correlates of platelet monoamine oxidase (MAO) activity in rhesus monkeys, Psychosom. Med. 37:80.Google Scholar
  80. Redmond, D. E., Murphy, D. L., Ziegler, M. G., Lake, C. R., and Baulu, J., 1975, Menstrual cycle and ovarian hormone effects on plasma and platelet monoamine oxidase (MAO) and plasma dopamine-beta-hydroxylase (DBH) activities in the rhesus monkey. Psychosom. Med. 37:417–428.PubMedGoogle Scholar
  81. Redmond, D. E., Baulu, J., Murphy, D. L., Loriaux, D. L., Ziegler, M. G., and Lake, C. R., 1976, Effects of testosterone on plasma and platelet monoamine oxidase and plasma dopamine β-hydroxylase activities in the male rhesus monkey, Psychosom. Med. 38:315–326.PubMedGoogle Scholar
  82. Robinson, D. S., Lovenberg, W., Keiser, H., and Sjoerdsma, J., 1968, Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo, Biochem. Pharmacol. 17:109–119.PubMedCrossRefGoogle Scholar
  83. Robinson, D. S., Davis, J. M., Nies, A., Ravaris, C. L., and Sylwester, D., 1971, Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets, Arch. Gen. Psychiatry 24:536–539.PubMedGoogle Scholar
  84. Rosenblatt, S., Chancey, J. D., and Leighton, W. P., 1969, The investigation of adrenergic metabolism with 7H3-norepinephrine in psychiatric disorders, J. Psychiatr. Res. 6:320–333.Google Scholar
  85. Rosenthal, D., 1971, Two adoption studies of heredity in the schizophrenic disorders, in: The Origin of Schizophrenia (M. Bleuler and J. Angst, eds.), pp. 21–34, Verlag Hans Huber, Berlin.Google Scholar
  86. Sandler, M., and Coveney, J., 1962, Placental monoamine-oxidase activity in toxemia of pregnancy, Lancet 1:1096–1098.PubMedCrossRefGoogle Scholar
  87. Sandler, M., and Youdim, M. B. H., 1972, Multiple forms of monoamine oxidase: Functional significance, Pharmacol. Rev. 24:331–348.PubMedGoogle Scholar
  88. Sandler, M., Carter, S. B., Goodwin, B. L., Ruthven, C. R. J., Youdim, M. B. H., Hanington, E., Cuthbert, M. F., and Pare, C. M. B., 1974a, Multiple forms of monoamine oxidase: Some in vivo correlations, in: Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes (E. Usdin, ed.), pp. 3–10, Raven Press, New York.Google Scholar
  89. Sandler, M., Youdim, M. B. H., and Hanington, E., 1974b, A phenylethylamine oxidizing defect in migraine, Nature 250:335–337.PubMedCrossRefGoogle Scholar
  90. Schildkraut, J. J., and Kety, S. S., 1967, Biogenic amines and emotion, Science 156:21–30.PubMedCrossRefGoogle Scholar
  91. Schwartz, M. A., Aikens, A. M., and Wyatt, R. J., 1974a, Monoamine oxidase activity in brains from schizophrenic and mentally normal individuals, Psychopharmacologia 38:319–328.PubMedCrossRefGoogle Scholar
  92. Schwartz, M. A., Wyatt, R. J., Yang, H-Y. T., and Neff, N. H., 1974b, Multiple forms of brain monoamine oxidase in schizophrenic and normal individuals, Arch. Gen. Psychiatry 31:557–560.PubMedGoogle Scholar
  93. Shasran, E. G., and Becker, R. E., 1975, Platelet monoamine oxidase in schizophrenics, Nature 253:659–660.CrossRefGoogle Scholar
  94. Sjoerdsma, A., Oates, J. A., Zaltzman, P., and Udenfriend, S., 1959a, Identification and assay of urinary tryptamine: Application as an index of monoamine oxidase inhibition in man, J. Pharmacol. Exp. Ther. 126:217–222.PubMedGoogle Scholar
  95. Sjoerdsma, A., Lovenberg, W., Oates, J. A., Grout, J. R., and Udenfriend, S., 1959b, Alterations in the pattern of amine excretion in man produced by a monoamine oxidase inhibitor, Science 130:225.PubMedCrossRefGoogle Scholar
  96. Squires, R. J., 1972, Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability; a comparison of eight mammalian species, in: Advances in Biochemical Psychopharmacology (E. Costa and P. Greengard, eds.), p. 335, Raven Press, New York.Google Scholar
  97. Stockley, I. H., 1973, Monoamine oxidase inhibitors Part l: Interactions with sympathomimetic amines, Pharm. J. 210:590–594; Part 2: Interactions with antihypertensive agents, hypoglycaemics, CNS depressants, narcotics and antiParkinsonian agents, Pharm. J. 211:95–98.Google Scholar
  98. Takahashi, Y., 1955, Amine oxidase activity of liver tissues obtained by needle biopsy together with other liver function tests on schizophrenic patients. A preliminary report, Folia Psychiatr. Neural. Jpn. 10:263–278.Google Scholar
  99. Thompson, R. H. S., and Tickner, A., 1949, Observations on the mono-amine oxidase activity of platelet and uterus, Biochem. J. 45:125–130.Google Scholar
  100. Tipton, K. F., 1973, Biochemical aspects of monoamine oxidase, Br. Med. Bull. 29:116–119.Google Scholar
  101. Utena, H., Kanamura, H., Suda, S., Nakamura, R., Machiyama, Y., and Takahashi, R., 1968, Studies on the regional distribution of the monoamine oxidase activity in the brains of schizophrenic patients, Proc. Jpn. Acad. 44:1078–1083.Google Scholar
  102. Vogel, W. H., Orfel, V., and Century, B., 1969, Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain, J. Pharmacol. Exp. Ther. 165:196–203.PubMedGoogle Scholar
  103. White, H. L., and Wu, J. C., 1975, Multiple binding sites of human brain monoamine oxidase as indicated by substrate competition, J. Neurochem. 25:21–26.PubMedCrossRefGoogle Scholar
  104. Wise, C. D., Baden, M. H., and Stein, L., 1974, Postmortem measurements of enzymes in human brain: Evidence of a central noradrenergic deficit in schizophrenia, J. Psychiatr. Res. 11:221–248.CrossRefGoogle Scholar
  105. Wittenborn, J. R., Plante, M., Burgess, F., and Livermore, N., 1961, The efficacy of electroconvulsive therapy, iproniazid and placebo in the treatment of young depressed women, J. Nerv. Ment. Dis. 133:316–332.PubMedCrossRefGoogle Scholar
  106. Wittenborn, J. R., Plante, M., Burgess, F., and Maurer, H. A., 1962, A comparison of imipramine, electroconvulsive therapy and placebo in the treatment of depressions, J. Nero. Ment. Dis. 135:131–137.CrossRefGoogle Scholar
  107. Wyatt, R. J., Fram, D. H., Kuffer, D. J., and Snyder, F., 1971, Total prolonged drug-induced REM sleep suppression in anxious-depressed patients, Arch. Gen. Psychiatry 24:145–155.PubMedGoogle Scholar
  108. Wyatt, R. J., Saavedra, J. M., and Axelrod, J., 1973, A dimethyltryptamine (DMT) forming enzyme in human blood, Am. J. Psychiatry 130:754–760.PubMedGoogle Scholar
  109. Yang, H-Y. T., and Neff, N. H., 1973, β-Phenylethylamine: A specific substrate for type B monoamine oxidase of brain, J. Pharmacol. Exp. Ther. 187:365–371.PubMedGoogle Scholar
  110. Youdim, M. B. H., and Sourkes, T. L., 1972, The flavin prosthetic group of purified rat liver mitochondrial monoamine oxidase, Adv. Biochem. Psychopharmacol. 5:45–54.PubMedGoogle Scholar
  111. Youdim, M. B. H., Collins, G. G. S., Sandler, M., Bevan Jones, A. B., Pare, C. M. B., and Nicholson, W. J., 1972, Human brain monoamine oxidase: Multiple forms and selective inhibitors, Nature 236:225–227.PubMedCrossRefGoogle Scholar
  112. Youdim, M. B. H., Woods, H. F., Mitchell, B., Grahame-Smith, D. G., and Callender, S., 1975, Human platelet monoamine oxidase activity in iron-deficiency anaemia, Clin. Sci. Mol. Med. 48:289–295.PubMedGoogle Scholar
  113. Zeller, E. A., Boshes, B., Davis, J. M., and Thorner, M., 1975, Molecular aberration in platelet monoamine oxidase in schizophrenia, Lancet 1:1385.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Dennis L. Murphy
    • 1
  1. 1.Clinical Neuropharmacology BranchNational Institute of Mental HealthBethesdaUSA

Personalised recommendations